Inhibiting metalloproteases with PD 166793 in heart failure: Impact on cardiac remodeling and beyond

Nina Kaludercic, Merry L. Lindsey, Barbara Tavazzi, Giuseppe Lazzarino, Nazareno Paolocci

Research output: Contribution to journalReview article

24 Citations (Scopus)

Abstract

Metalloproteinases (MMPs, also called matrixins) are extracellular proteolytic enzymes involved in the degradation of both matrix and nonmatrix proteins. Currently, 25 MMPs have been identified in humans, and the overexpression of one or more MMPs has been implicated in several pathologies, spanning from cancer to rheumathoid arthritis to cardiovascular disease. While research over the past 20 years has focused on understanding MMP biology and selectively inhibiting MMP activity, key issues that remain to be addressed include MMP roles in the context of normal versus pathological conditions and whether globally inhibiting MMPs improves or deteriorates overall organ function. In terms of cardiovascular disease, increased MMP expression has been demonstrated in the setting of myocardial ischemia, reperfusion injury, and during the progression to congestive heart failure. MMPs are also major contributors to the progression of atherosclerotic lesions. In this review, we focus on cardiovascular effects produced by PD 166793, a wide-broad spectrum MMP inhibitor, originally developed by Parke-Davis (now Pfizer). We will briefly review its structure, mechanism of action, and inhibitory capacity. Finally, we will illustrate the cardiac contexts, both in vivo and in vitro, in which PD166793 administration has proven beneficial.

Original languageEnglish (US)
Pages (from-to)24-37
Number of pages14
JournalCardiovascular Therapeutics
Volume26
Issue number1
DOIs
StatePublished - Mar 1 2008

Fingerprint

Metalloproteases
Matrix Metalloproteinases
Heart Failure
Cardiovascular Diseases
Myocardial Reperfusion Injury
Matrix Metalloproteinase Inhibitors
(R)-2-(4'-bromo-biphenyl-4-sulfonyl-amino)-3-methyl-butyric acid
Reperfusion Injury
Arthritis
Myocardial Ischemia
Peptide Hydrolases
Pathology
Research

Keywords

  • AMP deaminase
  • Cardiac energetics
  • Heart failure
  • Metalloproteinases
  • Myocardial fibrosis
  • PD166793
  • Ventricular remodeling

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

Inhibiting metalloproteases with PD 166793 in heart failure : Impact on cardiac remodeling and beyond. / Kaludercic, Nina; Lindsey, Merry L.; Tavazzi, Barbara; Lazzarino, Giuseppe; Paolocci, Nazareno.

In: Cardiovascular Therapeutics, Vol. 26, No. 1, 01.03.2008, p. 24-37.

Research output: Contribution to journalReview article

Kaludercic, Nina ; Lindsey, Merry L. ; Tavazzi, Barbara ; Lazzarino, Giuseppe ; Paolocci, Nazareno. / Inhibiting metalloproteases with PD 166793 in heart failure : Impact on cardiac remodeling and beyond. In: Cardiovascular Therapeutics. 2008 ; Vol. 26, No. 1. pp. 24-37.
@article{5ace10e8c2a64ab08c803678a5b801a5,
title = "Inhibiting metalloproteases with PD 166793 in heart failure: Impact on cardiac remodeling and beyond",
abstract = "Metalloproteinases (MMPs, also called matrixins) are extracellular proteolytic enzymes involved in the degradation of both matrix and nonmatrix proteins. Currently, 25 MMPs have been identified in humans, and the overexpression of one or more MMPs has been implicated in several pathologies, spanning from cancer to rheumathoid arthritis to cardiovascular disease. While research over the past 20 years has focused on understanding MMP biology and selectively inhibiting MMP activity, key issues that remain to be addressed include MMP roles in the context of normal versus pathological conditions and whether globally inhibiting MMPs improves or deteriorates overall organ function. In terms of cardiovascular disease, increased MMP expression has been demonstrated in the setting of myocardial ischemia, reperfusion injury, and during the progression to congestive heart failure. MMPs are also major contributors to the progression of atherosclerotic lesions. In this review, we focus on cardiovascular effects produced by PD 166793, a wide-broad spectrum MMP inhibitor, originally developed by Parke-Davis (now Pfizer). We will briefly review its structure, mechanism of action, and inhibitory capacity. Finally, we will illustrate the cardiac contexts, both in vivo and in vitro, in which PD166793 administration has proven beneficial.",
keywords = "AMP deaminase, Cardiac energetics, Heart failure, Metalloproteinases, Myocardial fibrosis, PD166793, Ventricular remodeling",
author = "Nina Kaludercic and Lindsey, {Merry L.} and Barbara Tavazzi and Giuseppe Lazzarino and Nazareno Paolocci",
year = "2008",
month = "3",
day = "1",
doi = "10.1111/j.1527-3466.2007.00034.x",
language = "English (US)",
volume = "26",
pages = "24--37",
journal = "Cardiovascular Therapeutics",
issn = "1755-5914",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Inhibiting metalloproteases with PD 166793 in heart failure

T2 - Impact on cardiac remodeling and beyond

AU - Kaludercic, Nina

AU - Lindsey, Merry L.

AU - Tavazzi, Barbara

AU - Lazzarino, Giuseppe

AU - Paolocci, Nazareno

PY - 2008/3/1

Y1 - 2008/3/1

N2 - Metalloproteinases (MMPs, also called matrixins) are extracellular proteolytic enzymes involved in the degradation of both matrix and nonmatrix proteins. Currently, 25 MMPs have been identified in humans, and the overexpression of one or more MMPs has been implicated in several pathologies, spanning from cancer to rheumathoid arthritis to cardiovascular disease. While research over the past 20 years has focused on understanding MMP biology and selectively inhibiting MMP activity, key issues that remain to be addressed include MMP roles in the context of normal versus pathological conditions and whether globally inhibiting MMPs improves or deteriorates overall organ function. In terms of cardiovascular disease, increased MMP expression has been demonstrated in the setting of myocardial ischemia, reperfusion injury, and during the progression to congestive heart failure. MMPs are also major contributors to the progression of atherosclerotic lesions. In this review, we focus on cardiovascular effects produced by PD 166793, a wide-broad spectrum MMP inhibitor, originally developed by Parke-Davis (now Pfizer). We will briefly review its structure, mechanism of action, and inhibitory capacity. Finally, we will illustrate the cardiac contexts, both in vivo and in vitro, in which PD166793 administration has proven beneficial.

AB - Metalloproteinases (MMPs, also called matrixins) are extracellular proteolytic enzymes involved in the degradation of both matrix and nonmatrix proteins. Currently, 25 MMPs have been identified in humans, and the overexpression of one or more MMPs has been implicated in several pathologies, spanning from cancer to rheumathoid arthritis to cardiovascular disease. While research over the past 20 years has focused on understanding MMP biology and selectively inhibiting MMP activity, key issues that remain to be addressed include MMP roles in the context of normal versus pathological conditions and whether globally inhibiting MMPs improves or deteriorates overall organ function. In terms of cardiovascular disease, increased MMP expression has been demonstrated in the setting of myocardial ischemia, reperfusion injury, and during the progression to congestive heart failure. MMPs are also major contributors to the progression of atherosclerotic lesions. In this review, we focus on cardiovascular effects produced by PD 166793, a wide-broad spectrum MMP inhibitor, originally developed by Parke-Davis (now Pfizer). We will briefly review its structure, mechanism of action, and inhibitory capacity. Finally, we will illustrate the cardiac contexts, both in vivo and in vitro, in which PD166793 administration has proven beneficial.

KW - AMP deaminase

KW - Cardiac energetics

KW - Heart failure

KW - Metalloproteinases

KW - Myocardial fibrosis

KW - PD166793

KW - Ventricular remodeling

UR - http://www.scopus.com/inward/record.url?scp=47049121031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47049121031&partnerID=8YFLogxK

U2 - 10.1111/j.1527-3466.2007.00034.x

DO - 10.1111/j.1527-3466.2007.00034.x

M3 - Review article

C2 - 18466418

AN - SCOPUS:47049121031

VL - 26

SP - 24

EP - 37

JO - Cardiovascular Therapeutics

JF - Cardiovascular Therapeutics

SN - 1755-5914

IS - 1

ER -